BBIO Stock Forecast & Price Target

BridgeBio Pharma is favored because Attruby is already generating meaningful commercial momentum, with Q2 US sales of $222MM, up 23% sequentially and 211% year over year, while royalty revenue rose to $15MM and the ATTR-CM market expanded 19% sequentially. Its outlook is further strengthened by three additional late-stage catalysts—ribitol with a PDUFA date of November 27, 2026, encaleret with a PDUFA date of May 8, 2027, and infigratinib with strong Phase 3 data, multiple FDA designations, and broad efficacy signals beyond growth. Taken together with about $1B of fresh capital, conservative expense management, and a path to profitability by the end of 2027, the company appears positioned to convert its pipeline into durable growth and cash flow.

BridgeBio Pharma is viewed negatively because its valuation depends on a concentrated set of late-stage assets that still face meaningful clinical, regulatory, and commercial risk, including limited adoption for ATTR-CM, second-to-market positioning versus Pfizer’s Vyndaqel/Vyndamax, and uncertainty around infigratinib’s U.S. uptake. The balance sheet adds pressure: the company ended Q2 with $720MM of cash, cash equivalents, and short-term restricted cash, down from $940MM in Q1, while carrying about $1.9B of debt, including $450MM due 2029, which raises refinancing and covenant risk if launches disappoint. Even with recent financing and expected flat cash burn this year, failure of the broader pipeline to deliver adequate safety, efficacy, and commercial traction could impair its ability to service debt and sustain operations.